Engaging the p53-dependent apoptotic signaling has been established as an important component of current AML therapies with proven clinical success and its synergistic enhancement by a DNA-PK inhibitor offers a new approach for potential therapeutic intervention. The gene discussed is TP53; the disease is acute myeloid leukemia.